CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.5%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) traded down 1.5% during mid-day trading on Thursday . The company traded as low as $58.62 and last traded at $58.83. 285,889 shares were traded during mid-day trading, a decline of 83% from the average session volume of 1,662,861 shares. The stock had previously closed at $59.72.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wolfe Research assumed coverage on CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Robert W. Baird raised their target price on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Citigroup cut their target price on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Finally, Chardan Capital raised their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $73.46.

Get Our Latest Research Report on CRSP

CRISPR Therapeutics Stock Down 3.5 %

The firm has a 50 day simple moving average of $57.31 and a two-hundred day simple moving average of $65.43.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. During the same quarter in the prior year, the business earned ($0.67) EPS. The company’s revenue was down 99.5% on a year-over-year basis. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.51 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $767,104.52. Following the sale, the chief executive officer now directly owns 203,705 shares in the company, valued at $15,941,953.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $767,104.52. Following the sale, the chief executive officer now directly owns 203,705 shares in the company, valued at $15,941,953.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the sale, the chief financial officer now owns 6,476 shares in the company, valued at $470,740.44. The disclosure for this sale can be found here. Insiders have sold a total of 55,709 shares of company stock worth $3,865,228 over the last three months. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. raised its holdings in CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,061 shares during the last quarter. ARK Investment Management LLC raised its holdings in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after purchasing an additional 1,372,986 shares during the last quarter. Norges Bank acquired a new position in CRISPR Therapeutics during the fourth quarter worth $38,661,000. Prime Capital Investment Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter worth $206,000. Finally, Baker Chad R raised its holdings in shares of CRISPR Therapeutics by 89.1% in the fourth quarter. Baker Chad R now owns 98,520 shares of the company’s stock worth $6,167,000 after acquiring an additional 46,420 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.